Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 4/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PPM1D | O15297 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15320760 | 0.94 | ALOX15 (0.76) | ALOX15HPGDSMN1; SMN2CASP3BRD4 | |
| SCHEMBL15319696 | 0.89 | ALOX15 (0.80) | ALOX15HPGDSMN1; SMN2CASP3BRD4 | |
| SCHEMBL15326450 | 0.88 | ALOX15 (0.79) | ALOX15HPGDSMN1; SMN2CASP3HDAC8 | |
| SCHEMBL15320847 | 0.85 | ALOX15 (0.88) | ALOX15HPGDSMN1; SMN2BRD4PTGER4 | |
| SCHEMBL15320804 | 0.84 | ALOX15 (0.83) | ALOX15HPGDSMN1; SMN2BRD4PTGER4 | |
| SCHEMBL15320844 | 0.84 | ALOX15 (0.78) | ALOX15HPGDSMN1; SMN2CASP3BRD4 | |
| SCHEMBL15320680 | 0.83 | ALOX15 (1.00) | ALOX15SMN1; SMN2CASP3BRD4PTGER4 | |
| SCHEMBL15321088 | 0.83 | ALOX15 (0.84) | ALOX15HPGDSMN1; SMN2CASP3BRD4 | |
| SCHEMBL15326449 | 0.82 | ALOX15 (0.75) | ALOX15HPGDSMN1; SMN2CASP3BRD4 | |
| SCHEMBL19239515 | 0.82 | ALOX15 (0.78) | ALOX15HPGDSMN1; SMN2BRD4PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233370-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-08-17 | — | — | US | disclosed |
| US-9580398-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150079035-A1 | Compounds, Compositions, and Methods For Modulating Ferroptosis and Treating Excitotoxic Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079035-A1 | Compounds, Compositions, and Methods For Modulating Ferroptosis and Treating Excitotoxic Disorders | AIFM2, GPX1, GPX4 | ALOX15 86/4885HPGD 516/4885SMN1; SMN2 434/4885 |
| US-20170233370-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | AIFM2, GPX1, GPX4 | ALOX15 93/4885HPGD 776/4885SMN1; SMN2 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.